key: cord-0708699-8ad1lxek
authors: Yokoyama, Yuhei; Terada, Yuriko; Nava, Ruben G.; Puri, Varun; Kreisel, Daniel; Patterson, G. Alexander; Hachem, Ramsey R.; Takahashi, Tsuyoshi
title: Coronavirus disease 2019 positivity immediately after lung transplantation: A case report
date: 2022-04-22
journal: Transplant Proc
DOI: 10.1016/j.transproceed.2022.03.032
sha: 7c393f4b6b3e9cd987bd1680017c9cce0bf28a6b
doc_id: 708699
cord_uid: 8ad1lxek

Management of coronavirus disease 2019 (COVID-19) in lung transplant recipients is challenging. We report a case of a 71-year-old male who underwent bilateral lung transplantation with an unexpected COVID-19. The patient had been fully vaccinated. The patient and donor tested negative for pre-transplant COVID-19. On routine bronchoscopy on day 1 after transplant, the COVID-19 test was positive. Mycophenolic mofetil and the 2nd dose of basiliximab were skipped, but tacrolimus and prednisone were continued. He was treated with casirivimab / imdevimab and remdesivir. He was discharged on day 14 and has had no episodes of acute rejection during the 3 months.

In December 2019, a novel coronavirus, designated as coronavirus disease 2019 (COVID-19), has rapidly spread, resulting in a global pandemic 1 . A concern about the susceptibility of immunocompromised patients to the worldwide pandemic of COVID-19 has been raised. Optimal management of immunosuppression and antiviral treatment is challenging in solid organ transplant recipients with COVID-19 infection. In addition to immunosuppression, lung transplant recipients are highly susceptible to serious disease due to COVID-19 2 . Throughout the pandemic, there have been concerns about patients and donors being infected with COVID-19 at the time of transplantation. Here, we present a rare case of a lung transplant recipient who was found to be COVID-19 positive the day following transplantation.

A 71-year-old man with chronic hypersensitivity pneumonitis (CHP) was referred to our center for evaluation 2 years prior to lung transplantation. His past medical history was notable for colon cancer 7 years ago without recurrence. A chest computed tomography (CT) scan showed interstitial fibrosis with ground-glass opacities bilaterally consistent with CHP. Pulmonary function testing at the time when he was listed showed forced vital capacity = 2.12 L (47% of predicted), forced expiratory volume in 1 second = 1.91 L (56% of predicted), total lung capacity = 3.76 L (51% of predicted) and diffusing capacity for carbon monoxide = 9.6 mL / mmHg / min (35% of predicted). Two months after listing, a suitable donor became available, and the patient was admitted to undergo transplantation.

The patient had received 2 doses of the COVID-19 vaccine followed by a booster dose 23 days before transplantation. On admission, he had dyspnea, cough, and fatigue, but these symptoms were attributed to his underlying lung disease. He did not have fever or other symptoms suggestive of COVID-19 infection. His pre-transplant nasopharyngeal (NP) swab polymerase chain reaction (PCR) for COVID-19 was negative, and the donor NP swab and bronchoalveolar lavage (BAL) PCR, 4 and 2 days before lung transplantation, respectively were also negative for COVID-19. He underwent bilateral lung transplantation with intra-operative extracorporeal membrane oxygenation support. On postoperative day (POD) 1, he underwent PCR test from NP, BAL and saliva for COVID-19, which found to be positive ( Figure 1 ). We suspected that the donor PCR may have been falsely negative. We performed anti-nucleocapsid antibody testing on donor blood because the donor had not been vaccinated, and this was negative. In retrospect, the recipient's wife endorsed respiratory symptoms suggestive of COVID-19, and she was advised to undergo testing; this was positive on POD 2. This suggested that the recipient and his wife were infected with COVID-19 before transplantation. The recipient had received the first dose of basiliximab on POD 0, but the second dose was held and mycophenolate mofetil was discontinued. He was maintained on tacrolimus and prednisone according to our program's immunosuppression protocol. He was treated with monoclonal antibody (casirivimab / imdevimab 600mg / 600mg) on POD 1 and remdesivir 200 mg for 5 days from POD 2. His postoperative course was uncomplicated and mycophenolate mofetil was restarted on POD 5. His chest X-ray did not show any abnormalities (Figure 2 ) when he was discharged on POD 14. The explanted lung pathology showed advanced interstitial fibrosis with honeycombing consistent with CPH. Follow-up COVID-19 PCR became negative 2 months after transplantation, and the recipient continues to do well without any episodes of acute rejection.

We report a rare case of a recipient who was diagnosed with COVID-19 the day after bilateral lung transplantation. In this case, COVID-19 PCR tests of both donor and recipient 48 hours prior to transplantation were negative, however, on POD 1, the recipient's PCR test from BAL was found to be positive. We subsequently discovered that the recipient's wife was also COVID-19 positive suggesting that both were infected preoperatively. Although a previous case of donor-transmitted COVID-19 infection has been reported in spite of a negative donor NP swab PCR 3 , our case is different in that the recipient was infected pre-transplant.

Balancing treatment of COVID-19 and management of immunosuppression in the immediate period following transplantation is challenging because although de-escalating immunosuppression can promote viral clearance, this may increase the risk of rejection. There are no current established guidelines or optimal treatment strategies for solid organ transplant recipients who develop COVID-19, but the administration of monoclonal antibodies early after viral exposure may enhance passive immunity and prevent progression to severe disease 4 . In addition, vaccination and booster dosing pre-operatively likely contributed to the prevention of severe disease in our patient. In this case, the second dose of basiliximab on POD 4 was held and mycophenolate mofetil was discontinued.

Decreasing immunosuppression, particularly withholding antimetabolites, has shown benefits in ameliorating viral infection in solid organ transplant recipients 5 . One report in liver transplant patients suggests that mycophenolic mofetil dose reduction or withdrawal may prevent severe COVID-19 disease 6 .

In conclusion, we described a challenging case of a lung transplant recipient who was found to be infected with COVID-19 on the day following transplantation. Although COVID-19 infection in lung transplant recipients can be fatal, aggressive treatment with monoclonal antibodies, remdesivir and de-escalation of immunosuppression was effective in our patient. In addition, pre-transplant vaccination and booster dosing likely mitigated the severity of the infection. 

Clinical characteristics of coronavirus disease 2019 in China

COVID-19 in lung transplant recipients

Donor to recipient transmission of SARS-CoV-2 by lung transplantation despite negative donor upper respiratory tract testing

Monoclonal antibodies for prevention and treatment of COVID-19

Viral infection after renal transplantation: surveillance and management

Epidemiological pattern, incidence, and outcomes of COVID-19 in liver transplant patients

Disclosures: None